- Drozd, Daniel R;
- Saag, Michael S;
- Westfall, Andrew O;
- Mathews, William Chris;
- Haubrich, Richard;
- Boswell, Stephen L;
- Cole, Stephen R;
- Porter, Donna;
- Kitahata, Mari M;
- Juday, Timothy;
- Rosenblatt, Lisa
We determined risk of virologic failure (VF) in individuals initiating tenofovir/emtricitabine/efavirenz as single versus multiple tablet regimens (MTR). We found no significant difference in the risk of VF, though did observe a trend toward more VF and M184 V mutations among persons initiating MTR. Temporal trends in care may have confounded results.
